3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Solid Tumors Harboring NTRK Fusion
2
Sarcoma
2
Thyroid Neoplasms
1
Salivary Gland Neoplasms
1
Neoplasms
1
Melanoma
1
Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Fluorouracil
255
Leucovorin
224
Oxaliplatin
218
Irinotecan
206
Bevacizumab
200
Capecitabine
144
Cetuximab
136
Panitumumab
68
Folfox protocol
63
regorafenib
50
Colonoscopy
44
pembrolizumab
42
IFL protocol
39
Radiotherapy
32
Nivolumab
31
Drug Therapy
27
trifluridine tipiracil drug combination
26
Gemcitabine
24
Blood Specimen Collection
23
Chemotherapy, Adjuvant
20
Surveys and Questionnaires
19
Celecoxib
19
Surgical Procedures, Operative
16
durvalumab
15
Neoadjuvant Therapy
15
Cyclophosphamide
14
Cisplatin
14
aflibercept
13
Standard of Care
13
Pemetrexed
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Colorectal Neoplasms
×
larotrectinib
×
Clear all
NCT02576431
2026-04-28
NAVIGATE
Bayer
Phase 2
Completed
215 enrolled
2 FDA